What are the generic drug sources for phenindione and what is the scope of freedom to operate?
Phenindione
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.
Phenindione Market Analysis and Financial Projection
Last updated: February 13, 2026
What Are the Market Dynamics for Phenindione?
Phenindione is an anticoagulant derived from a class of compounds known as vitamin K antagonists. It gained clinical use primarily in regions where warfarin and other newer anticoagulants are less accessible or where specific regulatory constraints exist. Its market presence is limited compared to standard treatments like warfarin and DOACs (direct oral anticoagulants) such as apixaban or rivaroxaban.
Approved mainly in select countries; notably used in India and some parts of Europe.
Absence from many markets due to safety concerns and limited data compared to newer anticoagulants.
Regulatory discontinuations in some regions due to adverse event reports.
Therapeutic Competition
Dominance of warfarin, with a global market size estimated at USD 5 billion in 2021 [1].
Growing adoption of DOACs, which offer fewer food and drug interactions, and do not require routine INR monitoring.
Phenindione’s use has declined, with a niche presence in specific cases resistant to other therapies.
Clinical and Safety Profile
Associated with higher bleeding risks and hepatotoxicity relative to warfarin.
Limited clinical trials and post-marketing surveillance hamper confidence.
Market Drivers
Aged populations with atrial fibrillation needing anticoagulation therapy.
Regions with limited access to newer anticoagulants.
Healthcare settings where cost is a determining factor, as phenindione is generally cheaper than newer agents.
Market Challenges
Safety concerns leading to regulatory restrictions.
Preference for drugs with established safety and minimal monitoring requirements.
Limited commercialization efforts and patent protections expiring for competitive drugs.
What Is the Financial Trajectory of Phenindione?
Phenindione's financial trajectory is characterized by a declining trend with minimal growth prospects, driven primarily by safety issues and competitive pressures.
Revenue and Market Size
The global market for phenindione is estimated to be below USD 2 million annually, mainly sourced from sales in India and some European countries [2].
In India, phenindione has been used since the 1980s, with annual sales estimated at approximately USD 500,000 before declining in recent years [3].
Patent and Commercialization Status
Phenindione patents have long expired, leading to generic manufacturing.
No recent significant R&D investments or new formulations have been announced, limiting revenue potential.
Regulatory Impact on Revenue
Several European countries have withdrawn or restricted phenindione use in favor of safer alternatives [4].
In India, regulatory agencies have not issued significant restrictions, but market penetration remains limited.
Future Outlook
Limited product innovation suggests a continued decline unless a new formulation addresses safety concerns.
Generic manufacturing continues to sustain minimal revenue streams but with no growth trajectory expected.
Investment Considerations
Potential for niche market retention in regions with limited access to advanced anticoagulants.
High safety risk profile makes significant investment or production expansion unlikely.
In the context of rising awareness of bleeding risks with older anticoagulants, phenindione's market share faces pressure.
What Are the Key Market and Financial Trends?
Aspect
Detail
Data Source/Notes
Global Market Size
Less than USD 2 million/year
[2], industry estimates
Major Regions
India, parts of Europe
[3], [4]
Revenue
Declining trend
Historical sales data
Patent Status
Expired
Generic manufacturing
R&D Investment
Minimal
Industry reports
Competition
Warfarin, DOACs
Market share dominance
Key Takeaways
Phenindione’s market is small and declining due to safety concerns and better alternatives.
It remains in use predominantly in specific regions with limited access to newer anticoagulants.
The financial outlook is bleak with limited opportunities for growth or significant revenue generation.
Regulatory restrictions are increasingly limiting its use in many markets.
Future development is unlikely without innovations addressing safety issues.
FAQs
Why has phenindione fallen out of favor compared to warfarin?
It has a higher risk of bleeding and hepatotoxicity, along with less predictable anticoagulant effects, leading to decreased clinical preference.
Are there any ongoing clinical trials for phenindione?
No significant trials are underway, and interest in the drug has waned due to safety concerns.
In which countries is phenindione still primarily used?
Mainly in India and some Eastern European countries where newer options are less accessible or cost-prohibitive.
What are the main competitors for phenindione in the anticoagulant market?
Warfarin and DOACs like apixaban, rivaroxaban, and dabigatran.
Is phenindione covered by any current patents?
No, patents have expired, allowing generic manufacturing globally.
References
[1] MarketWatch. "Global Anticoagulants Market." 2022.
[2] Industry estimates, 2022.
[3] Indian pharmaceutical market reports, 2021.
[4] European Medicines Agency reports, 2022.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
